Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide is an experimental hair loss treatment, with users discussing its availability and cost from sources like Anagen Inc, Actifolic, and MinoxidilMax. Some users express concerns about product authenticity and suggest waiting for further trial results to assess its safety and effectiveness.

The user has been using Finasteride for seven months to address hair loss but hasn't seen noticeable regrowth and is experiencing brittle, thinning hair with scalp issues. They are also using Salisia and Re’equil Salicylic Acid shampoo for potential psoriasis and are seeking advice from others with similar experiences.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.

The user has been using minoxidil 12.5% and finasteride 1mg for 7 months, experiencing significant hair regrowth. They are considering adding dutasteride and using a dermaroller for further improvement.

A user shared their 11-week post-op hair transplant results, noting they use only vitamins, not minoxidil or finasteride. Replies suggest starting finasteride to maintain results, with mixed opinions on the current progress.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

The conversation discusses using a combination of redensyl, capixyl, and procapil (RCP) for hair loss, with some users also mentioning minoxidil and finasteride. Users shared mixed experiences, with some suggesting "RevivHair Max Hair Stimulating Serum" for better results, while others reported no noticeable effects from using products like The Ordinary Multi-Peptide Serum.

The user has been using oral finasteride for two years and oral minoxidil for seven months to support hair regrowth. They are unsure about the progress due to inconsistent photo comparisons but note some minor side effects from finasteride.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Users inquire about experiences with Pyrilutamide Kx group buys.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

A user had a bad experience with MV Supplements when their Pyril powder and ethanol order leaked during shipping, making the products unusable. Despite contacting support and providing evidence, the company's return policy did not allow for a refund or replacement.

The user is excited about their hair regrowth after 10 weeks using oral finasteride, topical minoxidil, ketoconazole, dermarolling, and vitamin D. They've seen significant hair thickening and believe minoxidil and dermarolling are the main contributors to their progress.

The user shared their hair regrowth progress using a combination of treatments including finasteride, dutasteride, minoxidil, tretinoin, Sulfogenz, KX-826, low-level laser therapy, and microneedling. They plan to continue medication for another year before considering a hair transplant, noting steady improvement but not major changes.

After 7 months of using topical finasteride/minoxidil, microneedling, and Nizoral shampoo, the user believes they are seeing hair regrowth. They are seeking further advice to improve their results, excluding hair transplant options.

The user shared progress on hair regrowth after 7 months using Minoxidil 5% twice daily, Finasteride 1mg once daily, vitamin D3, and Neurobion injections. They encouraged others to persist with their treatments, noting visible improvements and expecting further gains.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.